équipe facteurs de persistance des cellules leucemiques

Team : Factors of persistence of leukemic cells

NEWS

OPALE, the organization for Partnerships in Leukemia

The team “Factors of persistence of leukemic cells” focused on the discovery of factors that contribute to the long-term persistence of leukemic cells such as tumor dormancy, and to the characterization of genomic markers predictive of the evolution of hematological malignancies.

The team is located in Institut pour la Recherche sur le Cancer de Lille www.ircl.org for its cell biology and in hematology laboratory and high throughput genomic technologies for CHU de Lille (Lille Academic Hospital) for its tumor cell bank and translational molecular biology activities. The team shares the same building with Flow cytometry and Cell sorting platforms and several team members are involved in both activities.

The team is historically linked with the Department of Clinical Hematology (Service des Maladies du Sang, CHU), the Laboratory of Hematology, and the Department of cytogenetic form the nearby academic hospital. Several team members are primary affiliated to the CHU, and research projects are directly issued from this high degree of integration.

> RESEARCHERS
> ENGINEERS / TECHNICIANS
> STUDENTS

RESEARCHERS

Bruno QuesnelProfessor QUESNEL Bruno, MD, PhD,HDR.
Head of “Factors of persitence of leukemic cells” team. PU-PH, Lille University Hospital.
Research: Tumor dormancy in leukemia.

bruno.quesnel(@)chru-lille.fr

Thierry IdziorekThierry IDZIOREK, Researcher- INSERM – HDR
Research: Tumor dormancy in leukemia and microfluidics.
Teaching: Master’s degree.
Responsabilités collectives : In charge of the cytometry facility (University of Lille)/In charge of the irradiator (University of Lille).

thierry.idziorek(@)inserm.fr

Marie-Hélène DavidMarie-Hélène DAVID, Researcher- INSERM, HDR
Research: Identification of oncogenic transcription factors in leukemias and solid tumors: validation of selective inhibitors.
Teaching: Master’s degree.
Responsabilités collectives: Contact person for radioprotection.

marie-helene.david(@)inserm.fr

Meyling CheokMeyling CHEOK, Researcher- INSERM, HDR
Research: My research team investigates the effect of genetic and non-genetic factors on intra- and inter-leukaemia heterogeneity and how this influences chemotherapy resistance and disease progression. We aim to develop tools to identify and track resistant leukaemia cells within the leukaemia bulk and to improve treatment to prevent or delay the evolution of drug resistance and subsequent disease relapse.
> CV complet

meyling.cheok(@)inserm.fr

Philippe MarchettiProfessor MARCHETTI Philippe, MD, PhD,HDR
Research: Mitochondrial metabolism in leukemic cell dormancy.
Teaching: Cell Biology.

philippe.marchetti(@)inserm.fr

Claude PreudhommeProfessor PREUDHOMME Claude, PharmD, PhD, HDR
PU-PH Hematology Institut, Lille University Hospital

Research: New genomic markers for the prognosis of hematological malignancies.

claude.preudhomme(@)chru-lille.fr

Catherine Roche-LestienneProfessor ROCHE-LESTIENNE Catherine, PharmD, PhD, HDR
PU-PH Medical Genetic Institut, Lille University Hospital.

catherine.roche(@)chru-lille.fr

Jérôme KluzaJérôme KLUZA, Associate Professor- University of Lille, HDR
Research: Mitochondrial metabolism of persistent myeloid leukemia cells after exposure to targeted therapies.
Teaching: Cell biology.
Responsabilités collectives : Responsable Plateau Technique : Métabolisme.

jerome.kluza(@)inserm.fr

Carine BrinsterCarine BRINSTER, Associate Professor- University of Lille, HDR
Research: Mechanisms leading to T lymphocyte deficiency associated with acute myeloid leukemias and the role of the immune response in leukemic persistence.
Teaching: Cell biology, Immunology.

carine.brinster(@)inserm.fr

Salomon ManierSalomon MANIER, MCU-PH CHU de Lille, HDR
Research: Genomic dependence and markers of clonal evolution in mature lymphoid malignancies.
Teaching: Myeloma, Lymphoma and Chronic Lymphoblastic Leukemia.

salomon.manier(@)chru-lille.fr

Yasmine TouilYasmine TOUIL, Ingénieure de Recherche -Université de Lille, HDR
Research: Mechanisms of tumor dormancy: genetic, epigenetic and proteomic signatures of dormant cells. Link with stem cells properties.
Responsabilités collectives : Animatrice des réunions scientifiques- Référent Site WEB, Cahier Électronique Laboratoire, SST.

yasmine.touil(@)inserm.fr

Xavier ThuruXavier THURU, Ingénieure de Recherche – Université de Lille
Research: In charge of drug discovery and development. Responsible of screening core facility.
Responsabilités collectives : Responsable Plateau Technique: Criblage de molécules, Référent Spectramax.

xavier.thuru(@)inserm.fr

Céline BerthonCéline BERTHON, MD, PhD
PH, Lille University Hospital

celine.berthon(@)chru-lille.fr

 

Stéphanie Poulain

Professor POULAIN Stéphanie, PharmD, PhD, HDR, PU-PH
Hematology Institut, Lille University Hospital
Faculty of Pharmaceutical Sciences, Lille

Research: Genomic and functional dependence in Waldenstrom’s disease.

stephanie.poulain(@)chru-lille.fr

Nicolas Duployez
Nicolas DUPLOYEZ, PharmD, PhD
PH Hematology Institut, Lille University Hospital

nicolas.duployez(@)chru-lille.fr

Olivier NIBOUREL, PharmD, PhD
PH Hematology Institut, Lille University Hospital

olivier.nibourel(@)chru-lille.fr

Christophe ROUMIER, PharmD, PhD
PH Hematology Institut, Lille University Hospital

christophe.roumier(@)chru-lille.fr

Alice MarceauAlice MARCEAU, PharmD
PH Hematology Institut, Lille University Hospital

alice.marceau(@)chru-lille.fr

Suman MitraDr Suman MITRA, Researcher PI CPER CANCER
Research project: Common gamma-chain (gc) family of cytokines, including IL-2, IL-15, IL-21 are critical regulator of T cell activity but their actions are often pleiotropic, which possess a major challenge for their use to treat diseases, including cancer.  Our research focuses on understanding molecular mechanisms by which these cytokines mediate their pleiotropic actions to identify strategies to utilize power of cytokines to modulate T cell responses in cancer. In particular, we are studing how cytokine signaling pathways can be fine-tuned to refine current immunotherapy drugs, including checkpoint blockade, CAR-T therapy as well as use cancer vaccine therapy.

suman.mitra(@)inserm.fr

Silvia GaggeroDr Silvia GAGGERO, Post-doctoral researcher
CPER Cancer- Suman MITRA’s group.

silvia.gaggero(@)inserm.fr

ENGINEERS/TECHNICIANS

Pauline Peyrouze
Pauline PEYROUZE, Engineer IRCL
Responsabilités collectives : Assistante-prévention, Référent Anibio, L2-Viro, L2 Culture cellulaire.

pauline.peyrouze(@)inserm.fr

Hassiba Bouaffia
Hassiba EL BOUAZZATI-BOUAFIA, Engineer assistant Inserm.
Responsabilités collectives : Assistante-prévention, Référent Agrément OGM, Las 4000.

hassiba.bouafia(@)inserm.fr

Aurélie Guillemette
Aurélie GUILLEMETTE, Technician UDL
Responsabilités collectives : Référent qPCR.

aurelie.guillemette(@)inserm.fr

Salim DEKIOUK, Technician, Lille University Hospital

salim.dekiouk(@)inserm.fr

Adeline Barthelemy

Dr Adeline BARTHELEMY, Research Engineer, PhD

adeline.barthelemy(@)inserm.fr

Géraldine Tellier
Dr Géraldine TELLIER, Associate Engineer, PhD
CPER Cancer- Suman MITRA’s group

geraldine.tellier(@)inserm.fr

Romain Magnez

Romain MAGNEZ, Engineer SATT

romain.magnez(@)inserm.fr

Adeline CozzaniAdeline COZZANI, Engineer UDL – Suman MITRA’s group

adeline.cozzani(@)inserm.fr

William Laine

William LAINE, Technician UDL

william.laine(@)univ-lille.fr

Morgane Tardy

Morgane TARDY, Technician SATT

morgane.tardy(@)inserm.fr

STUDENTS

Meriem Be KhoudMeriem BEN-KHOUD, PhD Student
Thesis topic: Identification of  “exhausted” T lymphocytes in patients with acute myeloid leukemia and monitoring their fate pre- and post-treatment by analyzing their TCR receptors: impact of the modulation of interleukin-2 signaling on the restoration of their memory phenotype.
Directed by: Dr Carine Brinster

meriem.ben-khoud(@)inserm.fr

Clara LewuillonClara LEWUILLON, PhD Student
Thesis topic: Calcium signature in immunological synapse in AML.
Directed by: Dr Yasmine Touil

clara.lewuillon(@)inserm.fr

Quentin FovezQuentin FOVEZ, PhD Student
Thesis topic: Metabolic regulation of mitochondrial spare capacity: a potential biomarker of AML persistance ?
Directed by: Dr Jérôme Kluza

quentin.fovez(@)inserm.fr

Fanny GonzalesFanny GONZALES, PhD Student
Thesis topic: Functions of CD81 in leukemogenesis and on prognosis in pediatric acute myeloid leukemia.
Directed by: Dr Meyling Cheok

fanny.gonzales(@)inserm.fr

Raeeka KhamariRaeeka KHAMARI, PhD Student
Thesis topic: Mitochondrial targeting of persitant cells in acute myeloid leukemia after exposure of targeted therapies.
Directed by: Dr Jérôme Kluza

raeeka.khamari(@)inserm.fr

Lama Hasan Bou IssaLama HASAN BOU ISSA, PhD Student
Thesis topic: Genomic dependence in multiple myeloma overexpressing myc.
Directed by: Dr Salomon Manier

lama.hasan-bou-issa(@)inserm.fr

Léa FlechonLéa FLECHON, PhD Student
Thesis topic: Genomic dependence in multiple myeloma.
Directed by: Dr Salomon Manier / Dr Thierry Idziorek

lea.flechon(@)univ-lille.fr

Eradication of the last tumor cell has been the holy grail of cancer research for decades. The idea was that if only a few persistent cancer cells remain in the body, relapse would inevitably occur. Thus, understanding the mechanisms that allow for the long-term persistence of these cells would help to avoid relapses. To address the question of persistence in human leukemia, we have built our research team around four strategic scientific axes.

– The first axis investigated by Bruno Quesnel, Yasmine Touil, Thierry Idziorek, Carine Brinster and Céline Berthon, was aimed at discovering, using experimental models and patient cohorts, factors that govern tumor dormancy and long term persistence of minimal residual disease (MRD) in leukemia and multiple myeloma. Results have specifically pinpointed the role of immunoescape (PD-L1, CCL2) and stemness in tumor dormancy.

More recently, the theme has been extended to tumor metabolism with the expertise of Philippe Marchetti and Jerome Kluza, who investigate dormancy/resistance of leukemia cells under tyrosine kinase inhibitors.

– The second axis explored by Claude Preudhomme, Catherine Roche-Lestienne, Stéphanie Poulain, Meyling Cheok, Olivier Nibourel, Christophe Roumier, Alice Marceau, and Nicolas Duployez, was dedicated to the systematic evaluation of new genomic markers of prognosis in hematological malignancies, notably AML, MDS, and Waldenstrom’s disease. The characterization of predictive markers of treatment failure and relapse in hematological malignancies has to yield results that can be easily translated into the daily routine. Biobanking of numerous national prospective clinical trials is done in our team at the tumor cell bank.

This axis has recently evolved under the impulsion of Meyling Cheok toward more functional characterization of leukemia cells, such as drug resistance and leukemia stemness, which are currently investigated in prospective patient cohorts from national study group such as ALFA and GFM.

– The third axis investigates new therapeutic strategies to target MRD: Marie-Hélène David develops new drugs that target transcription factor/DNA interaction, notably HOXA9. Xavier Thuru elaborates new methods (see PCBI platform/CANTHER platform) in collaboration with chemists to target protein/protein interactions in dormant tumor cells.

In 2016, Salomon Manier joined our team after five years at Irene Ghobrial lab at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. He specifically investigates Myc targeting in Multiple Myeloma, genomic dependence and markers of clonal evolution in mature lymphoid malignancies.

– The fourth axis investigates molecular biomarkers of therapeutic response and relapse to synthetic immunotherapy in heme malignancies with the goal to design and develop the next generation of synthetic immunotherapies with the improved durable response. The success of T cell engaging immunotherapies is not only dependent on their ability to recognize target tumor antigen but on maintaining sustained anti-tumor response within the immunosuppressive tumor microenvironment, which is critically regulated by cytokines. Dr Suman Mitra’s group is focused on understanding the role of gamma-chain cytokines, including IL-2, IL-7, IL-9, IL-15 and IL-21 that are critical for T cell survival, proliferation and function. The group is developing an innovative combination of cytokine based and T-cell based synthetic immunotherapies for the treatment of heme malignancies and cancers.

PUBLICATIONS

Publications 2020

Smol T, Thuillier C, Boudry-Labis E, Dieux-Coeslier A, Duban-Bedu B, Caumes R, Bouquillon S, Manouvrier-Hanu S, Roche-Lestienne C, Ghoumid J: Neurodevelopmental phenotype associated with CHD8-SUPT16H duplication. Neurogenetics 2020, 21:67-72.

Rio-Machin A, Vulliamy T, Hug N, Walne A, Tawana K, Cardoso S, Ellison A, Pontikos N, Wang J, Tummala H, Al Seraihi AFH, Alnajar J, Bewicke-Copley F, Armes H, Barnett M, Bloor A, Bodor C, Bowen D, Fenaux P, Green A, Hallahan A, Hjorth-Hansen H, Hossain U, Killick S, Lawson S, Layton M, Male AM, Marsh J, Mehta P, Mous R, Nomdedeu JF, Owen C, Pavlu J, Payne EM, Protheroe RE, Preudhomme C, Pujol-Moix N, Renneville A, Russell N, Saggar A, Sciuccati G, Taussig D, Toze CL, Uyttebroeck A, Vandenberghe P, Schlegelberger B, Ripperger T, Steinemann D, Wu J, Mason J, Page P, Akiki S, Reay K, Cavenagh JD, Plagnol V, Caceres JF, Fitzgibbon J, Dokal I: The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. Nat Commun 2020, 11:1044.

Paubelle E, Zylbersztejn F, Maciel TT, Carvalho C, Mupo A, Cheok M, Lieben L, Sujobert P, Decroocq J, Yokoyama A, Asnafi V, Macintyre E, Tamburini J, Bardet V, Castaigne S, Preudhomme C, Dombret H, Carmeliet G, Bouscary D, Ginzburg YZ, de The H, Benhamou M, Monteiro RC, Vassiliou GS, Hermine O, Moura IC: Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow. Cell Rep 2020, 30:739-54 e4.

Manier S: On the road to molecular prognostication in SMM. Leukemia 2020, 34:331-2.

Hermans D, Gautam S, Garcia-Canaveras JC, Gromer D, Mitra S, Spolski R, Li P, Christensen S, Nguyen R, Lin JX, Oh J, Du N, Veenbergen S, Fioravanti J, Ebina-Shibuya R, Bleck C, Neckers LM, Rabinowitz JD, Gattinoni L, Leonard WJ: Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8(+) T cell stemness and antitumor immunity. Proc Natl Acad Sci U S A 2020, 117:6047-55.

Gazeau N, Derrieux C, Nibourel O, Berthon C, Grardel N, Goursaud L, Boyer T, Dumezy F, Coiteux V, Quesnel B, Preudhomme C, Roche-Lestienne C, Duployez N: Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia. Leukemia 2020.

Fournier E, Duployez N, Ducourneau B, Raffoux E, Turlure P, Caillot D, Thomas X, Marceau-Renaut A, Chantepie S, Malfuson JV, Lemasle E, Cheok M, Celli-Lebras K, Guerin E, Terre C, Lambert J, Pautas C, Dombret H, Castaigne S, Preudhomme C, Boissel N: Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood 2020, 135:542-6.

Fournier E, Debord C, Soenen V, Trillot N, Gonzales F, Tintiller V, Terriou L, Derrieux C, Abou Chahla W, Paris C, Berthon C, Boyer T, Lambilliotte A, Boisseau P, Wuilleme S, Fouassier M, Susen S, Preudhomme C, Duployez N: Baseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignancies. Br J Haematol 2020.

Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Diez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Gotze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellstrom-Lindberg E, Zeidan AM, Ades L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF: Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med 2020, 382:140-51.

Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J: A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia 2020, 34:224-33.

 

Publications 2019

Lambert M., Alioui M., Jambon S., Depauw S., Van Seuningen I., David-Cordonnier M.-H. Direct and indirect targeting of HOXA9 transcription factor in acute myeloid leukemia. Cancers 2019, 11(6), 837-875.

Depauw S., Lambert M., Jambon S., Paul A., Peixoto P., Nhili R., Marongiu L., Figeac M., Dassi C., Paul-Constant C., Billoré B., Kumar A., Farahat A.A., Ismail M.A., Mineva E., Sweat D.P., Stephens C.E., Boykin D.W., Wilson W.D., David-Cordonnier M.-H. Heterocyclic Diamidine DNA ligands as HOXA9 Transcription Factor Inhibitors: Design, Molecular Evaluation and Cellular Consequences in HOXA9-Dependant Leukemia Cell Model. J. Med. Chem., 2019 Feb 14;62(3):1306-1329.

Liberelle, M., R. Magnez, X. Thuru, Y. Bencheikh, S. Ravez, C. Quenon, A. S. Drucbert, C. Foulon, P. Melnyk, I. V. Seuningen, and N. Lebegue. 2019. ‘MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis’, Sci Rep, 9: 16678.

Lucescu, L., A. Ghinet, S. Shova, R. Magnez, X. Thuru, A. Farce, B. Rigo, D. Belei, J. Dubois, and E. Bicu. 2019. ‘Exploring isoxazoles and pyrrolidinones decorated with the 4,6-dimethoxy-1,3,5-triazine unit as human farnesyltransferase inhibitors’, Arch Pharm (Weinheim), 352: e1800227.

Germain, N., Dessein, AF., Vienne,JC., Dobbelaere, D., Mention,K.,  Joncquel,M., Dekiouk, S., Laine, W., Kluza, J.*, and Marchetti, P.*. First-line screening of OXPHOS deficiencies using microscale oxygraphy in human skin fibroblasts: a preliminary study. (* coseniorship author)

Martinez-Fabregas J, Wilmes S, Wang L, Hafer M, Pohler E, Lokau J, Garbers C, Cozzani A, Piehler J, Kazemian M, Mitra S, Moraga Gonzalez I. Kinetics of cytokine receptor trafficking determine signaling and functional selectivity. Elife. 2019 Nov 27;8. pii: e49314. doi: 10.7554/eLife.49314. [Epub ahead of print]

Van de Wyngaert Z, Carpentier B, Pascal L, Lionne-Huyghe P, Leduc I, Srour M, Vasseur M, Demarquette H, Terriou L, Herbaux C, Manier S, Bossard JB, Barbieux S, Chauvet P, Willaume A, Nudel M, Bories C, Gibier JB, Facon T, Boyle EM. Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population. Br J Haematol. 2019 Nov 19. doi: 10.1111/bjh.16282.

Manier S. On the road to molecular prognostication in SMM. Leukemia. 2019 Nov 12. doi: 10.1038/s41375-019-0627-1.

Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J. Leukemia. 2019 Aug 19. doi: 10.1038/s41375-019-0539-0.

Jovanović KK, Escure G, Demonchy J, Willaume A, Van de Wyngaert Z, Farhat M, Chauvet P, Facon T, Quesnel B, Manier S. Deregulation and Targeting of TP53 Pathway in Multiple Myeloma. Front Oncol. 2019 Jan 9;8:665. doi: 10.3389/fonc.2018.00665. eCollection 2018. Review.

Boyer T, Gonzales F, Barthélémy A, Marceau-Renaut A, Peyrouze P, Guihard S, Lepelley P, Plesa A, Nibourel O, Delattre C, Wetterwald M, Pottier N, Plantier I, Botton S, Dombret H, Berthon C, Preudhomme C, Roumier C, Cheok M. Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study. Cancers (Basel). 2019 Sep 6;11(9). pii: E1323. doi: 10.3390/cancers11091323.

Moreno Leon L, Gautier M, Allan R, Ilié M, Nottet N, Pons N, Paquet A, Lebrigand K, Truchi M, Fassy J, Magnone V, Kinnebrew G, Radovich M, Cheok MH, Barbry P, Vassaux G, Marquette CH, Ponzio G, Ivan M, Pottier N, Hofman P, Mari B, Rezzonico R. Oncogene. 2019 Nov;38(46):7146-7165. doi: 10.1038/s41388-019-0935-y. Epub 2019 Aug 15.

Publications 2018

Lambert M., Jambon S., Depauw S., David-Cordonnier M.-H. Targeting transcription factors for cancer treatment. Molecules, 2018 Jun 19;23(6), pii:E1479., doi: 10.3390/molecules23061479.

Irena Sović*, Samy Jambon, Sandra Kraljević Pavelić, Elitza Markova-Car, Nataša Ilić, Sabine Depauw, Marie-Hélène David-Cordonnier*, Grace Karminski-Zamola. Synthesis, antitumor activity and DNA binding features of benzothiazolyl and benzimidazolyl substituted isoindolines. Bioorg. Med. Chem, 2018, 26(8), 1950-1960. (*co-corresponding author)

Segaoula, Z., A. Primot, F. Lepretre, B. Hedan, E. Bouchaert, K. Minier, L. Marescaux, F. Serres, S. Galiegue-Zouitina, C. Andre, B. Quesnel, X. Thuru, and D. Tierny. 2018. ‘Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology’, BMC Cancer, 18: 1219.

Leclercq, B., Kluza, J., Antherieu, S., Sotty, J., Alleman, LY., Coddeville, P. Lo Guidice, JM., Marchetti, P., Garçon, G. Mitochondrion : a sensitive target for the toxicity of healthy and chronic obstructive pulmonary diseased human bonchial epithelial cells repedtedly exposed to air pollution-derived PM2.5. Environ Pollut. 2018 ; 243(Pt B):1434-1449.

Quesnel B. CAR T-cells: A John von Neumann legacy? Curr Res Transl Med. 2018.

Sović I, Jambon S, Kraljević Pavelić S, Markova-Car E, Ilić N, Depauw S, David-Cordonnier MH, Karminski-Zamola G. Synthesis, antitumor activity and DNA binding features of benzothiazolyl and benzimidazolyl substituted isoindolines. Bioorg Med Chem. 2018.

Gibault F, Coevoet M, Sturbaut M, Farce A, Renault N, Allemand F, Guichou JF, Drucbert AS, Foulon C, Magnez R, Thuru X, Corvaisier M, Huet G, Chavatte P, Melnyk P, Bailly F, Cotelle P. Toward the Discovery of a Novel Class of YAP⁻TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP⁻TEAD Protein⁻Protein Interface. Cancers (Basel). 2018.

Khamari R, Trinh A, Gabert PE, Corazao-Rozas P, Riveros-Cruz S, Balayssac S, Malet-Martino M, Dekiouk S, Joncquel Chevalier Curt M, Maboudou P, Garçon G, Ravasi L, Guerreschi P, Mortier L, Quesnel B, Marchetti P, Kluza J. Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors. Cell Death Dis. 2018.

Cindrić M, Perić M, Kralj M, Martin-Kleiner I, David-Cordonnier MH, Paljetak HČ, Matijašić M, Verbanac D, Karminski-Zamola G, Hranjec M. Antibacterial and antiproliferative activity of novel 2-benzimidazolyl- and 2-benzothiazolyl-substituted benzo[b]thieno-2-carboxamides. Mol Divers. 2018.

Marinangeli C, Kluza J, Marchetti P, Buée L, Vingtdeux V. Study of AMPK-Regulated Metabolic Fluxes in Neurons Using the Seahorse XFe Analyzer. Methods Mol Biol. 2018.

Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, Rodon P, Van Droogenbroeck J, Qiu L, Cavo M, Van de Velde A, Lahuerta JJ, Allangba O, Lee JH, Boyle E, Perrot A, Moreau P, Manier S, Attal M, Roussel M, Mohty M, Mary JY, Civet A, Costa B, Tinel A, Gaston-Mathé Y, Facon T. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia. 2018.

Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, Moschetta M, Mishima Y, Roccaro A, Detappe A, Liu CJ, Sacco A, Huynh D, Tai YT, Robbins MD, Azzi J, Ghobrial IM. Antibody dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab. Mol Cancer Ther. 2018.

Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine TH, Manier S, Mishima Y, Murakami N, Bustoros M, Pistofidis RS, Reidy M, Shen YJ, Rahmat M, Lukyanchykov P, Karreci ES, Tsukamoto S, Shi J, Takagi S, Huynh D, Sacco A, Tai YT, Chesi M, Bergsagel PL, Roccaro AM, Azzi J, Ghobrial IM. Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. J Clin Invest. 2018.

Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M, Liu CJ, Mishima Y, Kokubun K, Manier S, Salem K, Huynh D, Sacco A, Forward JA, Roccaro A, Battinelli EM, Ghobrial IM. Platelets enhance Multiple Myeloma progression via IL-1beta upregulation. Clin Cancer Res. 2018.

Prata PH, Bally C, Prebet T, Recher C, Venton G, Thomas X, Raffoux E, Pigneux A, Cluzeau T, Desoutter J, Gay J, Preudhomme C, Fenaux P, Adès L. NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents. Haematologica. 2018.

Renneville A, Attias P, Thomas X, Bally C, Hayette S, Farhat H, Eclache V, Marceau-Renaut A, Cassinat B, Feuillard J, Terré C, Delabesse E, Park S, Lejeune J, Chevret S, Adès L, Preudhomme C, Fenaux P. Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. Leukemia. 2018.

Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. EBioMedicine. 2018.

Donadieu J, Lamant M, Fieschi C, Sicre de Fontbrune F, Caye A, Ouachee M, Beaupain B, Bustamante J, Poirel HA, Isidor B, Van Den Neste E, Neel A, Nimubona S, Toutain F, Barlogis V, Schleinitz N, Leblanc T, Rohrlich P, Suarez F, Ranta D, Abou Chahla W, Bruno B, Terriou L, Francois S, Lioure B, Ahle G, Bachelerie F, Preudhomme C, Delabesse E, Cavé H, Bellanné-Chantelot C, Pasquet M; French GATA2 working party. Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. Haematologica. 2018.

Itzykson R, Duployez N, Fasan A, Decool G, Marceau-Renaut A, Meggendorfer M, Jourdan E, Petit A, Lapillonne H, Micol JB, Cornillet-Lefebvre P, Ifrah N, Leverger G, Dombret H, Boissel N, Haferlach T, Preudhomme C. Clonal interference of signaling mutations holds prognostic relevance in core binding factor acute myeloid leukemia. Blood. 2018.

Boyer T, Gonzales F, Plesa A, Peyrouze P, Barthelemy A, Guihard S, Quesnel B, Roumier C, Preudhomme C, Cheok M. Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up. J Vis Exp. 2018.

Ali A, Penneroux J, Dal Bello R Jr, Massé A, Quentin S, Unnikrishnan A, Hernandez L, Raffoux E, Ben Abdelali R, Renneville A, Preudhomme C, Pimanda J, Dombret H, Soulier J, Fenaux P, Clappier E, Adès L, Puissant A, Itzykson R. Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia. Leukemia. 2018.

Willekens C, Renneville A, Broutin S, Saada V, Micol JB, Delahousse J, Poinsignon V, Bories C, Berthon C, Itzykson R, Boissel N, Quivoron C, Terroir-Cassou-Mounat M, Bosq J, Preudhomme C, Paci A, Penard-Lacronique V, De Botton S. Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. Leukemia. 2018.

Ferret Y, Boissel N, Helevaut N, Madic J, Nibourel O, Marceau-Renaut A, Bucci M, Geffroy S, Celli-Lebras K, Castaigne S, Thomas X, Terré C, Dombret H, Preudhomme C, Renneville A. Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. Haematologica. 2018.

Duployez N, Boudry-Labis E, Roumier C, Boissel N, Petit A, Geffroy S, Helevaut N, Celli-Lebras K, Terré C, Fenneteau O, Cuccuini W, Luquet I, Lapillonne H, Lacombe C, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C. SNP-array lesions in core binding factor acute myeloid leukemia. Oncotarget. 2018.

Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Dohner K, Roboz GJ, Ossenkoppele GJ. Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party. Blood. 2018.

Petit A, Trinquand A, Chevret S, Ballerini P, Cayuela JM, Grardel N, Touzart A, Brethon B, Lapillonne H, Schmitt C, Thouvenin S, Michel G, Preudhomme C, Soulier J, Landman-Parker J, Leverger G, Macintyre E, Baruchel A, Asnafi V. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. Blood. 2018.

Marino P, Touzani R, Perrier L, Rouleau E, Kossi DS, Zhaomin Z, Charrier N, Goardon N, Preudhomme C, Durand-Zaleski I, Borget I, Baffert S. Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study. Eur J Hum Genet. 2018.

Marchetti P, Trinh A, Khamari R, Kluza J. Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors. Biochim Biophys Acta. 2018.

Manier SK, Richter LHJ, Schaper J, Maurer HH, Meyer MR. Different in vitro and in vivo tools for elucidating the human metabolism of alpha-cathinone-derived drugs of abuse. Drug Test Anal. 2018.

Duployez N, Abou Chahla W, Lejeune S, Marceau-Renaut A, Letizia G, Boyer T, Geffroy S, Peyrouze P, Grardel N, Nelken B, Michel G, Bertrand Y, Preudhomme C. Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia. Eur J Haematol. 2018.

Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M, Liu CJ, Mishima Y, Kokubun K, Manier S, Salem K, Huynh D, Sacco A, Forward JA, Roccaro A, Battinelli EM, Ghobrial IM. Platelets enhance Multiple Myeloma progression via IL-1beta upregulation. Clin Cancer Res. 2018.

Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Dohner K, Roboz GJ, Ossenkoppele GJ. Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party. Blood. 2018.

Petit A, Trinquand A, Chevret S, Ballerini P, Cayuela JM, Grardel N, Touzart A, Brethon B, Lapillonne H, Schmitt C, Thouvenin S, Michel G, Preudhomme C, Soulier J, Landman-Parker J, Leverger G, Macintyre E, Baruchel A, Asnafi V. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. Blood. 2018;131(3):289-300.

Marino P, Touzani R, Perrier L, Rouleau E, Kossi DS, Zhaomin Z, Charrier N, Goardon N, Preudhomme C, Durand-Zaleski I, Borget I, Baffert S. Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study. Eur J Hum Genet. 2018.

Marchetti P, Trinh A, Khamari R, Kluza J. Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors. Biochim Biophys Acta. 2018;1862(4):999-1005.

Manier SK, Richter LHJ, Schaper J, Maurer HH, Meyer MR. Different in vitro and in vivo tools for elucidating the human metabolism of alpha-cathinone-derived drugs of abuse. Drug Test Anal. 2018.

Duployez N, Abou Chahla W, Lejeune S, Marceau-Renaut A, Letizia G, Boyer T, Geffroy S, Peyrouze P, Grardel N, Nelken B, Michel G, Bertrand Y, Preudhomme C. Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia. Eur J Haematol. 2018;100(1):104-107.

Publications 2017

Vial Y, Lachenaud J, Verloes A, Besnard M, Fenneteau O, Lainey E, Marceau-Renaut A, Preudhomme C, Baruchel A, Cave H, Drunat S. Down-syndrome-like acute megakaryoblastic leukemia in a patient with Cornelia de Lange syndrome. Haematologica. 2017.

Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Pigneux A, Vey N, Reman O, Simon M, Recher C, Cahn JY, Hermine O, Castaigne S, Celli-Lebras K, Ifrah N, Preudhomme C, Terre C, Dombret H. Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. J Clin Oncol. 2017;35(11):1223-1230.

Teyssier AC, Lapillonne H, Pasquet M, Ballerini P, Baruchel A, Ducassou S, Fenneteau O, Petit A, Cuccuini W, Ragu C, Preudhomme C, Mercher T, Sirvent N, Leverger G. Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial. Pediatr Hematol Oncol. 2017;34(8):425-427.

Tawana K, Rio-Machin A, Preudhomme C, Fitzgibbon J. Familial CEBPA-mutated acute myeloid leukemia. Semin Hematol. 2017;54(2):87-93.

Struski S, Lagarde S, Bories P, Puiseux C, Prade N, Cuccuini W, Pages MP, Bidet A, Gervais C, Lafage-Pochitaloff M, Roche-Lestienne C, Barin C, Penther D, Nadal N, Radford-Weiss I, Collonge-Rame MA, Gaillard B, Mugneret F, Lefebvre C, Bart-Delabesse E, Petit A, Leverger G, Broccardo C, Luquet I, Pasquet M, Delabesse E. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis. Leukemia. 2017;31(3):565-572.

Selimoglu-Buet D, Badaoui B, Benayoun E, Toma A, Fenaux P, Quesnel B, Etienne G, Braun T, Abermil N, Morabito M, Droin N, Solary E, Wagner-Ballon O. Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. Blood. 2017;130(6):832-835.

Salson M, Giraud M, Caillault A, Grardel N, Duployez N, Ferret Y, Duez M, Herbert R, Rocher T, Sebda S, Quief S, Villenet C, Figeac M, Preudhomme C. High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones. Leuk Res. 2017;53:1-7.

Sacco A, Kawano Y, Moschetta M, Zavidij O, Huynh D, Reagan M, Mishima Y, Manier S, Park J, Morgan E, Takagi S, Wong KK, Carrasco R, Ghobrial IM, Roccaro AM. A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation. Am J Hematol. 2017;92(8):E138-E145.

Poulain S, Roumier C, Bertrand E, Renneville A, Caillault-Venet A, Doye E, Geffroy S, Sebda S, Nibourel O, Nudel M, Herbaux C, Renaud L, Tomowiak C, Guidez S, Tricot S, Roche-Lestienne C, Quesnel B, Preudhomme C, Leleu X. TP53 Mutation and Its Prognostic Significance in Waldenstrom’s Macroglobulinemia. Clin Cancer Res. 2017;23(20):6325-6335.

Nibourel O, Guihard S, Roumier C, Pottier N, Terre C, Paquet A, Peyrouze P, Geffroy S, Quentin S, Alberdi A, Abdelali RB, Renneville A, Demay C, Celli-Lebras K, Barbry P, Quesnel B, Castaigne S, Dombret H, Soulier J, Preudhomme C, Cheok MH. Copy-number analysis identified new prognostic marker in acute myeloid leukemia. Leukemia. 2017;31(3):555-564.

Mohamed AM, Balsat M, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Tigaud I, Hayette S, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet M, Ceraulo A, Mortreux F, Wattel E. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML. Leuk Res. 2017;56:21-28.

Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud M, Perilla-Glen A, Aljawai Y, Huynh D, Roccaro AM, Sacco A, Capelletti M, Detappe A, Alignani D, Anderson KC, Munshi NC, Prosper F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson VA, Michor F, San Miguel JF, Ghobrial IM. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017;19(1):218-224.

Minnema MC, Kimby E, D’Sa S, Fornecker LM, Poulain S, Snijders TJ, Kastritis E, Kremer S, Fitsiori A, Simon L, Davi F, Lunn M, Castillo JJ, Patterson CJ, Le Garff-Tavernier M, Costopoulos M, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica. 2017;102(1):43-51.

Micol JB, Pastore A, Inoue D, Duployez N, Kim E, Lee SC, Durham BH, Chung YR, Cho H, Zhang XJ, Yoshimi A, Krivtsov A, Koche R, Solary E, Sinha A, Preudhomme C, Abdel-Wahab O. ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nat Commun. 2017;8:15429.

Meunier M, Ancelet S, Lefebvre C, Arnaud J, Garrel C, Pezet M, Wang Y, Faure P, Szymanski G, Duployez N, Preudhomme C, Biard D, Polack B, Cahn JY, Moulis JM, Park S. Reactive oxygen species levels control NF-kappaB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes. Oncotarget. 2017;8(62):105510-105524.

Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100-113.

Manier S, Powers JT, Sacco A, Glavey SV, Huynh D, Reagan MR, Salem KZ, Moschetta M, Shi J, Mishima Y, Roche-Lestienne C, Leleu X, Roccaro AM, Daley GQ, Ghobrial IM. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma. Leukemia. 2017;31(4):853-860.

Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, Roccaro AM, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial IM. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017;129(17):2429-2436.

Manier S, Leleu X, Avet-Loiseau H. [Circulating exosomal microRNA as biomarkers in mutiple myeloma]. Med Sci (Paris). 2017;33(11):939-941.

Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, Ebright RY, Shi J, Park J, Glavey SV, Devine WG, Liu CJ, Leleu X, Quesnel B, Roche-Lestienne C, Snyder JK, Brown LE, Gray N, Bradner J, Whitesell L, Porco JA, Jr., Ghobrial IM. Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Sci Transl Med. 2017;9(389).

Magnez R, Thiroux B, Taront S, Segaoula Z, Quesnel B, Thuru X. PD-1/PD-L1 binding studies using microscale thermophoresis. Sci Rep. 2017;7(1):17623.

Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A, Dumezy F, Feuillard J, Genevieve F, Guerin E, Guy J, Jouault H, Lepelley P, Maynadie M, Solly F, Ballon OW, Preudhomme C, Baruchel A, Dombret H, Ifrah N, Bene MC. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia. Hematol Oncol. 2017.

Herbaux C, Bertrand E, Marot G, Roumier C, Poret N, Soenen V, Nibourel O, Roche-Lestienne C, Broucqsault N, Galiegue-Zouitina S, Boyle EM, Fouquet G, Renneville A, Tricot S, Morschhauser F, Preudhomme C, Quesnel B, Poulain S, Leleu X. BACH2 promotes indolent clinical presentation in Waldenstrom macroglobulinemia. Oncotarget. 2017;8(34):57451-57459.

Halby L, Menon Y, Rilova E, Pechalrieu D, Masson V, Faux C, Bouhlel MA, David-Cordonnier MH, Novosad N, Aussagues Y, Samson A, Lacroix L, Ausseil F, Fleury L, Guianvarc’h D, Ferroud C, Arimondo PB. Rational Design of Bisubstrate-Type Analogues as Inhibitors of DNA Methyltransferases in Cancer Cells. J Med Chem. 2017;60(11):4665-4679.

Gonzales F, Cheok M. [Copy-number analysis identifies new prognostic marker in acute myeloid leukemia]. Med Sci (Paris). 2017;33(11):929-932.

Glavey SV, Naba A, Manier S, Clauser K, Tahri S, Park J, Reagan MR, Moschetta M, Mishima Y, Gambella M, Rocci A, Sacco A, O’Dwyer ME, Asara JM, Palumbo A, Roccaro AM, Hynes RO, Ghobrial IM. Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. Leukemia. 2017;31(11):2426-2434.

Dulery R, Nibourel O, Gauthier J, Elsermans V, Behal H, Coiteux V, Magro L, Renneville A, Marceau A, Boyer T, Quesnel B, Preudhomme C, Duhamel A, Yakoub-Agha I. Impact of Wilms’ tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. Bone Marrow Transplant. 2017;52(4):539-543.

Driss V, Lepretre F, Briche I, Mopin A, Villenet C, Figeac M, Quesnel B, Brinster C. Sub-clonal analysis of the murine C1498 acute myeloid leukaemia cell line reveals genomic and immunogenic diversity. Immunol Lett. 2017;192:27-34.

Cindric M, Jambon S, Harej A, Depauw S, David-Cordonnier MH, Kraljevic Pavelic S, Karminski-Zamola G, Hranjec M. Novel amidino substituted benzimidazole and benzothiazole benzo[b]thieno-2-carboxamides exert strong antiproliferative and DNA binding properties. Eur J Med Chem. 2017;136:468-479.

Chesnais V, Arcangeli ML, Delette C, Rousseau A, Guermouche H, Lefevre C, Bondu S, Diop M, Cheok M, Chapuis N, Legros L, Raynaud S, Willems L, Bouscary D, Lauret E, Bernard OA, Kosmider O, Pflumio F, Fontenay M. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes. Blood. 2017;129(4):484-496.

Chauveau A, Nibourel O, Tondeur S, Paz DL, Mansier O, Paul F, Wemeau M, Preudhomme C, Lippert E, Ugo V. Absence of CALR mutations in JAK2-negative polycythemia. Haematologica. 2017;102(1):e15-e16.

Bertrand E, Jouy N, Manier S, Fouquet G, Guidez S, Boyle E, Noel S, Tomowiak C, Herbaux C, Schraen S, Preudhomme C, Quesnel B, Poulain S, Leleu X. Role of IRF4 in resistance to immunomodulatory (IMid) compounds((R)) in Waldenstrom’s macroglobulinemia. Oncotarget. 2017;8(68):112917-112927.

Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol. 2017;28(3):468-477.

Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, Lemasle E, Marolleau JP, Nibourel O, Berthon C, Raffoux E, Pigneux A, Rodriguez C, Vey N, Cayuela JM, Hayette S, Braun T, Coude MM, Terre C, Celli-Lebras K, Dombret H, Preudhomme C, Boissel N. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. J Clin Oncol. 2017;35(2):185-193.

Balducci E, Nivaggioni V, Boudjarane J, Bouriche L, Rahal I, Bernot D, Alazard E, Duployez N, Grardel N, Arnoux I, Lafage-Pochitaloff M, Michel G, Nadel B, Loosveld M. Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy. Ann Hematol. 2017;96(9):1579-1581.

Andre F, Trinh A, Balayssac S, Maboudou P, Dekiouk S, Malet-Martino M, Quesnel B, Idziorek T, Kluza J, Marchetti P. Metabolic rewiring in cancer cells overexpressing the glucocorticoid-induced leucine zipper protein (GILZ): Activation of mitochondrial oxidative phosphorylation and sensitization to oxidative cell death induced by mitochondrial targeted drugs. Int J Biochem Cell Biol. 2017;85:166-174.

Publications 2016

Willekens C, Blanchet O, Renneville A, Cornillet-Lefebvre P, Pautas C, Guieze R, Ifrah N, Dombret H, Jourdan E, Preudhomme C, Boissel N. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. Haematologica. 2016;101(3):328-335.

Touil Y, Segard P, Ostyn P, Begard S, Aspord C, El Machhour R, Masselot B, Vandomme J, Flamenco P, Idziorek T, Figeac M, Formstecher P, Quesnel B, Polakowska R. Melanoma dormancy in a mouse model is linked to GILZ/FOXO3A-dependent quiescence of disseminated stem-like cells. Sci Rep. 2016;6:30405.

Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia. 2016;30(4):897-905.

Thepot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prebet T, Park S, Stamatoullas A, Guerci-Bresler A, Cheze S, Tertian G, Choufi B, Legros L, Bastie JN, Delaunay J, Chaury MP, Sanhes L, Wattel E, Dreyfus F, Vey N, Chermat F, Preudhomme C, Fenaux P, Gardin C. A randomized phase II trial of azacitidine +/- epoetin-beta in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. Haematologica. 2016;101(8):918-925.

Segaoula Z, Leclercq J, Verones V, Flouquet N, Lecoeur M, Ach L, Renault N, Barczyk A, Melnyk P, Berthelot P, Thuru X, Lebegue N. Synthesis and Biological Evaluation of N-[2-(4-Hydroxyphenylamino)-pyridin-3-yl]-4-methoxy-benzenesulfonamide (ABT-751) Tricyclic Analogues as Antimitotic and Antivascular Agents with Potent in Vivo Antitumor Activity. J Med Chem. 2016;59(18):8422-8440.

Salem KZ, Moschetta M, Sacco A, Imberti L, Rossi G, Ghobrial IM, Manier S, Roccaro AM. Exosomes in Tumor Angiogenesis. Methods Mol Biol. 2016;1464:25-34.

Roche-Lestienne C, Boudry-Labis E, Mozziconacci MJ. Cytogenetics in the management of “chronic myeloid leukemia”: an update by the Groupe francophone de cytogenetique hematologique (GFCH). Ann Biol Clin (Paris). 2016;74(5):511-515.

Roccaro AM, Sacco A, Shi J, Chiarini M, Perilla-Glen A, Manier S, Glavey S, Aljawai Y, Mishima Y, Kawano Y, Moschetta M, Correll M, Improgo MR, Brown JR, Imberti L, Rossi G, Castillo JJ, Treon SP, Freedman ML, Van Allen EM, Hide W, Hiller E, Rainville I, Ghobrial IM. Exome sequencing reveals recurrent germ line variants in patients with familial Waldenstrom macroglobulinemia. Blood. 2016;127(21):2598-2606.

Qassemyar A, Gabert PE, Kluza J, Duquennoy-Martinot V, Mortier L, Marchetti P, Guerreschi P. Patient-derived tumor xenograft strategies for informed management of patients with metastatic melanoma. Melanoma Res. 2016;26(3):245-253.

Poulain S, Roumier C, Venet-Caillault A, Figeac M, Herbaux C, Marot G, Doye E, Bertrand E, Geffroy S, Lepretre F, Nibourel O, Decambron A, Boyle EM, Renneville A, Tricot S, Daudignon A, Quesnel B, Duthilleul P, Preudhomme C, Leleu X. Genomic Landscape of CXCR4 Mutations in Waldenstrom Macroglobulinemia. Clin Cancer Res. 2016;22(6):1480-1488.

Perin N, Nhili R, Cindric M, Bertosa B, Vusak D, Martin-Kleiner I, Laine W, Karminski-Zamola G, Kralj M, David-Cordonnier MH, Hranjec M. Amino substituted benzimidazo[1,2-a]quinolines: Antiproliferative potency, 3D QSAR study and DNA binding properties. Eur J Med Chem. 2016;122:530-545.

Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, Bastie JN, Legrand O, Raffoux E, Plesa A, Wagner-Ballon O, Cornet E, Salaun V, Preudhomme C, Thomas X, Pautas C, Chantepie S, Turlure P, Castaigne S, Dombret H, Feuillard J. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood. 2016;127(17):2157-2160.

Odore E, Lokiec F, Cvitkovic E, Bekradda M, Herait P, Bourdel F, Kahatt C, Raffoux E, Stathis A, Thieblemont C, Quesnel B, Cunningham D, Riveiro ME, Rezai K. Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. Clin Pharmacokinet. 2016;55(3):397-405.

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Gorlich D, Buchner T, Hiddemann W, Berdel WE, Wormann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Lowenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540(7633):433-437.

Moschetta M, Mishima Y, Kawano Y, Manier S, Paiva B, Palomera L, Aljawai Y, Calcinotto A, Unitt C, Sahin I, Sacco A, Glavey S, Shi J, Reagan MR, Prosper F, Bellone M, Chesi M, Bergsagel LP, Vacca A, Roccaro AM, Ghobrial IM. Targeting vasculogenesis to prevent progression in multiple myeloma. Leukemia. 2016;30(5):1103-1115.

Mopin A, Driss V, Brinster C. A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model. J Vis Exp. 2016(116).

Mohamed AM, Balsat M, Thenoz M, Koering C, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Michallet M, Thomas X, Nicolini F, Solly F, Guyotat D, Campos L, Wattel E, Mortreux F. Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). Oncotarget. 2016;7(3):2889-2909.

Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M, Chautard E, Auboeuf D, Fenaux P, Braun T, Itzykson R, de Botton S, Quesnel B, Commes T, Jourdan E, Vainchenker W, Bernard O, Pata-Merci N, Solier S, Gayevskiy V, Dinger ME, Cowley MJ, Selimoglu-Buet D, Meyer V, Artiguenave F, Deleuze JF, Preudhomme C, Stratton MR, Alexandrov LB, Padron E, Ogawa S, Koscielny S, Figueroa M, Solary E. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016;7:10767.

Manier S, Salem KZ, Liu D, Ghobrial IM. Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. Am Soc Clin Oncol Educ Book. 2016;35:e400-406.

Manier S, Salem K, Glavey SV, Roccaro AM, Ghobrial IM. Genomic Aberrations in Multiple Myeloma. Cancer Treat Res. 2016;169:23-34.

Manier S, Kawano Y, Bianchi G, Roccaro AM, Ghobrial IM. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma. Curr Opin Hematol. 2016;23(4):426-433.

Lemal R, Bard-Sorel S, Montrieul L, Bay JO, Ravinet A, Ledoux-Pilon A, Cagnard N, Bailly S, Morel P, Charlotte F, Leleu X, Poulain S, Dechelotte PJ, Hermine O, Leblond V, Tournilhac O, Guieze R. TCL1 expression patterns in Waldenstrom macroglobulinemia. Mod Pathol. 2016;29(1):83-88.

Le Rouzic O, Kone B, Kluza J, Marchetti P, Hennegrave F, Olivier C, Kervoaze G, Vilain E, Mordacq C, Just N, Perez T, Bautin N, Pichavant M, Gosset P. Cigarette smoke alters the ability of human dendritic cells to promote anti-Streptococcus pneumoniae Th17 response. Respir Res. 2016;17(1):94.

Latger-Cannard V, Philippe C, Bouquet A, Baccini V, Alessi MC, Ankri A, Bauters A, Bayart S, Cornillet-Lefebvre P, Daliphard S, Mozziconacci MJ, Renneville A, Ballerini P, Leverger G, Sobol H, Jonveaux P, Preudhomme C, Nurden P, Lecompte T, Favier R. Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. Orphanet J Rare Dis. 2016;11:49.

Glavey SV, Manier S, Sacco A, Salem K, Kawano Y, Bouyssou J, Ghobrial IM, Roccaro AM. Epigenetics in Multiple Myeloma. Cancer Treat Res. 2016;169:35-49.

Gaudette BT, Dwivedi B, Chitta KS, Poulain S, Powell D, Vertino P, Leleu X, Lonial S, Chanan-Khan AA, Kowalski J, Boise LH. Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenstrom macroglobulinemia. Oncogene. 2016;35(4):479-490.

Ferret Y, Caillault A, Sebda S, Duez M, Grardel N, Duployez N, Villenet C, Figeac M, Preudhomme C, Salson M, Giraud M. Multi-loci diagnosis of acute lymphoblastic leukaemia with high-throughput sequencing and bioinformatics analysis. Br J Haematol. 2016;173(3):413-420.

Errea A, Cayet D, Marchetti P, Tang C, Kluza J, Offermanns S, Sirard JC, Rumbo M. Lactate Inhibits the Pro-Inflammatory Response and Metabolic Reprogramming in Murine Macrophages in a GPR81-Independent Manner. PLoS One. 2016;11(11):e0163694.

Emadali A, Hoghoughi N, Duley S, Hajmirza A, Verhoeyen E, Cosset FL, Bertrand P, Roumier C, Roggy A, Suchaud-Martin C, Chauvet M, Bertrand S, Hamaidia S, Rousseaux S, Josserand V, Charles J, Templier I, Maeda T, Bruder-Costa J, Chaperot L, Plumas J, Jacob MC, Bonnefoix T, Park S, Gressin R, Tensen CP, Mecucci C, Macintyre E, Leroux D, Brambilla E, Nguyen-Khac F, Luquet I, Penther D, Bastard C, Jardin F, Lefebvre C, Garnache F, Callanan MB. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. Blood. 2016;127(24):3040-3053.

Duployez N, Nibourel O, Ducourneau B, Grardel N, Boyer T, Bories C, Darre S, Coiteux V, Berthon C, Preudhomme C, Roche-Lestienne C. Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript. Eur J Haematol. 2016;97(4):399-402.

Duployez N, Micol JB, Boissel N, Petit A, Geffroy S, Bucci M, Lapillonne H, Renneville A, Leverger G, Ifrah N, Dombret H, Abdel-Wahab O, Jourdan E, Preudhomme C. Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21). Leuk Lymphoma. 2016;57(1):199-200.

Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, Lapillonne H, Renneville A, Ragu C, Figeac M, Celli-Lebras K, Lacombe C, Micol JB, Abdel-Wahab O, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016;127(20):2451-2459.

Duployez N, Lejeune S, Renneville A, Preudhomme C. Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists. Expert Rev Hematol. 2016;9(12):1189-1202.

Duployez N, Grzych G, Ducourneau B, Alarcon Fuentes M, Grardel N, Boyer T, Abou Chahla W, Bruno B, Nelken B, Clappier E, Preudhomme C. NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors. Haematologica. 2016;101(4):e133-134.

Desoutter J, Gay J, Berthon C, Ades L, Gruson B, Geffroy S, Plantier I, Marceau A, Helevaut N, Fernandes J, Bemba M, Stalnikiewicz L, Frimat C, Labreuche J, Nibourel O, Roumier C, Figeac M, Fenaux P, Quesnel B, Renneville A, Duhamel A, Preudhomme C. Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine. Leukemia. 2016;30(6):1416-1418.

Corazao-Rozas P, Guerreschi P, Andre F, Gabert PE, Lancel S, Dekiouk S, Fontaine D, Tardivel M, Savina A, Quesnel B, Mortier L, Marchetti P, Kluza J. Mitochondrial oxidative phosphorylation controls cancer cell’s life and death decisions upon exposure to MAPK inhibitors. Oncotarget. 2016;7(26):39473-39485.

Chesnais V, Renneville A, Toma A, Lambert J, Passet M, Dumont F, Chevret S, Lejeune J, Raimbault A, Stamatoullas A, Rose C, Beyne-Rauzy O, Delaunay J, Solary E, Fenaux P, Dreyfus F, Preudhomme C, Kosmider O, Fontenay M. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood. 2016;127(6):749-760.

Ceroi A, Masson D, Roggy A, Roumier C, Chague C, Gauthier T, Philippe L, Lamarthee B, Angelot-Delettre F, Bonnefoy F, Perruche S, Biichle S, Preudhomme C, Macintyre E, Lagrost L, Garnache-Ottou F, Saas P. LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis. Blood. 2016;128(23):2694-2707.

Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA, Leleu X, McMaster M, Merlini G, Minnema MC, Morra E, Owen RG, Poulain S, Stone MJ, Tam C, Varettoni M, Dimopoulos MA, Treon SP, Kastritis E. Recommendations for the diagnosis and initial evaluation of patients with Waldenstrom Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstrom Macroglobulinaemia. Br J Haematol. 2016;175(1):77-86.

Cabannes-Hamy A, Lemal R, Goldwirt L, Poulain S, Amorim S, Perignon R, Berger J, Brice P, De Kerviler E, Bay JO, Sauvageon H, Beldjord K, Mourah S, Tournilhac O, Thieblemont C. Efficacy of ibrutinib in the treatment of Bing-Neel syndrome. Am J Hematol. 2016;91(3):E17-19.

Boyle E, Manier S, Lejeune J, Fouquet G, Guidez S, Bonnet S, Debarri H, Demarquette H, Dulery R, Gay J, Hennache B, Onraed B, Faucompre JL, Schraen S, Facon T, Avet-Loiseau H, Chevret S, Leblond V, Harding S, Leleu X. IgMkappa and IgMlambda Measurements for the Assessment of Patients with Waldenstrom’s Macroglobulinaemia. Clin Cancer Res. 2016;22(20):5152-5158.

Boyer T, Guihard S, Roumier C, Peyrouze P, Gonzales F, Berthon C, Quesnel B, Preudhomme C, Behal H, Duhamel A, Roche-Lestienne C, Cheok M. Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia. Oncotarget. 2016;7(38):62377-62385.

Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, Kahatt C, Quesnel B, Michallet M, Recher C, Lokiec F, Preudhomme C, Dombret H. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 2016;3(4):e186-195.

Antony-Debre I, Duployez N, Bucci M, Geffroy S, Micol JB, Renneville A, Boissel N, Dhedin N, Rea D, Nelken B, Berthon C, Leblanc T, Mozziconacci MJ, Favier R, Heller PG, Abdel-Wahab O, Raslova H, Latger-Cannard V, Preudhomme C. Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia. Leukemia. 2016;30(4):999-1002.

Andre F, Corazao-Rozas P, Idziorek T, Quesnel B, Kluza J, Marchetti P. GILZ overexpression attenuates endoplasmic reticulum stress-mediated cell death via the activation of mitochondrial oxidative phosphorylation. Biochem Biophys Res Commun. 2016;478(2):513-520.

Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, Morschhauser F, Karlin L, Broussais F, Rezai K, Herait P, Kahatt C, Lokiec F, Salles G, Facon T, Palumbo A, Cunningham D, Zucca E, Thieblemont C. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016;3(4):e196-204.

Abdelhamid E, Besbes S, Renneville A, Nibourel O, Helevaut N, Preudhomme C, Soua Z. Minimal Residual Disease assessment of IDH1/2 mutations in Acute Myeloid Leukemia by LNA-RQ-PCR. Tunis Med. 2016;94(3):190-197.

Publications 2015

White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, Barbany G, Boeckx N, Bench A, Catherwood M, Cayuela JM, Chudleigh S, Clench T, Colomer D, Daraio F, Dulucq S, Farrugia J, Fletcher L, Foroni L, Ganderton R, Gerrard G, Gineikiene E, Hayette S, El Housni H, Izzo B, Jansson M, Johnels P, Jurcek T, Kairisto V, Kizilors A, Kim DW, Lange T, Lion T, Polakova KM, Martinelli G, McCarron S, Merle PA, Milner B, Mitterbauer-Hohendanner G, Nagar M, Nickless G, Nomdedeu J, Nymoen DA, Leibundgut EO, Ozbek U, Pajic T, Pfeifer H, Preudhomme C, Raudsepp K, Romeo G, Sacha T, Talmaci R, Touloumenidou T, Van der Velden VH, Waits P, Wang L, Wilkinson E, Wilson G, Wren D, Zadro R, Ziermann J, Zoi K, Muller MC, Hochhaus A, Schimmel H, Cross NC, Emons H. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. Leukemia. 2015;29(2):369-376.

Trabelsi MS, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, Perino A, Brighton CA, Sebti Y, Kluza J, Briand O, Dehondt H, Vallez E, Dorchies E, Baud G, Spinelli V, Hennuyer N, Caron S, Bantubungi K, Caiazzo R, Reimann F, Marchetti P, Lefebvre P, Backhed F, Gribble FM, Schoonjans K, Pattou F, Tailleux A, Staels B, Lestavel S. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun. 2015;6:7629.

Tomellini E, Touil Y, Lagadec C, Julien S, Ostyn P, Ziental-Gelus N, Meignan S, Lengrand J, Adriaenssens E, Polakowska R, Le Bourhis X. Nerve growth factor and proNGF simultaneously promote symmetric self-renewal, quiescence, and epithelial to mesenchymal transition to enlarge the breast cancer stem cell compartment. Stem Cells. 2015;33(2):342-353.

Tierny D, Serres F, Segaoula Z, Bemelmans I, Bouchaert E, Petain A, Brel V, Couffin S, Marchal T, Nguyen L, Thuru X, Ferre P, Guilbaud N, Gomes B. Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma. Clin Cancer Res. 2015;21(23):5314-5323.

Tawana K, Wang J, Renneville A, Bodor C, Hills R, Loveday C, Savic A, Van Delft FW, Treleaven J, Georgiades P, Uglow E, Asou N, Uike N, Debeljak M, Jazbec J, Ancliff P, Gale R, Thomas X, Mialou V, Dohner K, Bullinger L, Mueller B, Pabst T, Stelljes M, Schlegelberger B, Wozniak E, Iqbal S, Okosun J, Araf S, Frank AK, Lauridsen FB, Porse B, Nerlov C, Owen C, Dokal I, Gribben J, Smith M, Preudhomme C, Chelala C, Cavenagh J, Fitzgibbon J. Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood. 2015;126(10):1214-1223.

Smol T, Nibourel O, Marceau-Renaut A, Celli-Lebras K, Berthon C, Quesnel B, Boissel N, Terre C, Thomas X, Castaigne S, Dombret H, Preudhomme C, Renneville A. Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. Leuk Res. 2015;39(12):1443-1447.

Simonetta F, Posa M, Villard J, Marceau-Renaut A, Preudhomme C, Samii K, Chizzolini C. Restoration of hematopoiesis in a case of myelodysplastic syndrome associated with systemic lupus erythematosus treated with rituximab. Ann Hematol. 2015;94(7):1247-1249.

Selimoglu-Buet D, Wagner-Ballon O, Saada V, Bardet V, Itzykson R, Bencheikh L, Morabito M, Met E, Debord C, Benayoun E, Nloga AM, Fenaux P, Braun T, Willekens C, Quesnel B, Ades L, Fontenay M, Rameau P, Droin N, Koscielny S, Solary E. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood. 2015;125(23):3618-3626.

SavreuxLenglet G, Depauw S, David-Cordonnier MH. Protein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove Adducts. Int J Mol Sci. 2015;16(11):26555-26581.

Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai YT, Shi J, Zhang Y, Reagan MR, Huynh D, Kawano Y, Sahin I, Chiarini M, Manier S, Cea M, Aljawai Y, Glavey S, Morgan E, Pan C, Michor F, Cardarelli P, Kuhne M, Ghobrial IM. CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Rep. 2015;12(4):622-635.

Poulain S, Boyle EM, Tricot S, Demarquette H, Doye E, Roumier C, Duthilleul P, Preudhomme C, Maurage CA, Morschhauser F. Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma. Br J Haematol. 2015;170(2):285-287.

Poret N, Fu Q, Guihard S, Cheok M, Miller K, Zeng G, Quesnel B, Troussard X, Galiegue-Zouitina S, Shelley CS. CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy. Cancer Res. 2015;75(18):3902-3911.

Peterlin P, Renneville A, Ben Abdelali R, Nibourel O, Thomas X, Pautas C, de Botton S, Raffoux E, Cayuela JM, Boissel N, Terre C, Celli-Lebras K, Castaigne S, Preudhomme C, Gardin C, Dombret H. Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. Haematologica. 2015;100(5):e196-199.

Paul A, Nanjunda R, Kumar A, Laughlin S, Nhili R, Depauw S, Deuser SS, Chai Y, Chaudhary AS, David-Cordonnier MH, Boykin DW, Wilson WD. Mixed up minor groove binders: Convincing A.T specific compounds to recognize a G.C base pair. Bioorg Med Chem Lett. 2015;25(21):4927-4932.

Marchetti P, Guerreschi P, Mortier L, Kluza J. Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics. Int J Cell Biol. 2015;2015:283145.

Marceau-Renaut A, Guihard S, Castaigne S, Dombret H, Preudhomme C, Cheok M. Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations. Am J Hematol. 2015;90(5):E93-94.

Letouzey M, Penther D, Roche-Lestienne C, Nelken B, Devoldere C, Vannier JP, Schneider P. Detection of dicentric chromosome (9;20) in paediatric B-cell acute lymphoblastic leukaemia: prognostic significance. Ann Hematol. 2015;94(2):187-193.

Lehraiki A, Cerezo M, Rouaud F, Abbe P, Allegra M, Kluza J, Marchetti P, Imbert V, Cheli Y, Bertolotto C, Ballotti R, Rocchi S. Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib. Cell Discov. 2015;1:15030.

Lefevre G, Copin MC, Roumier C, Aubert H, Avenel-Audran M, Grardel N, Poulain S, Staumont-Salle D, Seneschal J, Salles G, Ghomari K, Terriou L, Leclech C, Morati-Hafsaoui C, Morschhauser F, Lambotte O, Ackerman F, Trauet J, Geffroy S, Dumezy F, Capron M, Roche-Lestienne C, Taieb A, Hatron PY, Dubucquoi S, Hachulla E, Prin L, Labalette M, Launay D, Preudhomme C, Kahn JE. CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder. Haematologica. 2015;100(8):1086-1095.

Khaznadar Z, Boissel N, Agaugue S, Henry G, Cheok M, Vignon M, Geromin D, Cayuela JM, Castaigne S, Pautas C, Raffoux E, Lachuer J, Sigaux F, Preudhomme C, Dombret H, Dulphy N, Toubert A. Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion. J Immunol. 2015;195(6):2580-2590.

Kawano Y, Moschetta M, Manier S, Glavey S, Gorgun GT, Roccaro AM, Anderson KC, Ghobrial IM. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015;263(1):160-172.

Herbaux C, Duployez N, Badens C, Poret N, Gardin C, Decamp M, Eclache V, Daliphard S, Murati A, Cony-Makhoul P, Cheze S, Beve B, Lacoste C, Prebet T, Hunault-Berger M, Maloisel F, Renneville A, Figeac M, Stamatoullas-Bastard A, Bastard C, Fenaux P, Preudhomme C, Rose C. Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis. Am J Hematol. 2015;90(8):737-738.

Harel S, Cherait A, Berthon C, Willekens C, Park S, Rigal M, Brechignac S, Thepot S, Quesnel B, Gardin C, Ades L, Fenaux P, Braun T. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leuk Res. 2015;39(5):501-504.

Guilhot J, Preudhomme C, Mahon FX, Guilhot F. Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules. Cancer. 2015;121(4):490-497.

Guery T, Roumier C, Berthon C, Renneville A, Preudhomme C, Quesnel B. B7-H3 protein expression in acute myeloid leukemia. Cancer Med. 2015;4(12):1879-1883.

Gros C, Fleury L, Nahoum V, Faux C, Valente S, Labella D, Cantagrel F, Rilova E, Bouhlel MA, David-Cordonnier MH, Dufau I, Ausseil F, Mai A, Mourey L, Lacroix L, Arimondo PB. New insights on the mechanism of quinoline-based DNA Methyltransferase inhibitors. J Biol Chem. 2015;290(10):6293-6302.

Glavey SV, Huynh D, Reagan MR, Manier S, Moschetta M, Kawano Y, Roccaro AM, Ghobrial IM, Joshi L, O’Dwyer ME. The cancer glycome: carbohydrates as mediators of metastasis. Blood Rev. 2015;29(4):269-279.

Fouquet G, Guidez S, Petillon MO, Louni C, Ohyba B, Dib M, Poulain S, Herbaux C, Martin A, Thielemans B, Brice P, Choquet S, Bakala J, Bories C, Demarquette H, Nudel M, Tournilhac O, Arnulf B, LeGouill S, Morel P, Banos A, Karlin L, Salles G, Leblond V, Leleu X. Lenalidomide is safe and active in Waldenstrom macroglobulinemia. Am J Hematol. 2015;90(11):1055-1059.

Duployez N, Willekens C, Marceau-Renaut A, Boudry-Labis E, Preudhomme C. Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. Expert Rev Hematol. 2015;8(1):43-56.

Duployez N, Boudry-Labis E, Decool G, Grzych G, Grardel N, Abou Chahla W, Preudhomme C, Roche-Lestienne C. Diagnosis of intrachromosomal amplification of chromosome 21 (iAMP21) by molecular cytogenetics in pediatric acute lymphoblastic leukemia. Clin Case Rep. 2015;3(10):814-816.

Driss V, Quesnel B, Brinster C. Monocyte chemoattractant protein 1 (MCP-1/CCL2) contributes to thymus atrophy in acute myeloid leukemia. Eur J Immunol. 2015;45(2):396-406.

Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B, Gardin C, Chretien ML, Sebda S, Figeac M, Berthon C, Quesnel B, Boissel N, Castaigne S, Dombret H, Renneville A, Preudhomme C. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget. 2015;6(39):42345-42353.

Bruzzoni-Giovanelli H, Gonzalez JR, Sigaux F, Villoutreix BO, Cayuela JM, Guilhot J, Preudhomme C, Guilhot F, Poyet JL, Rousselot P. Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia. Oncotarget. 2015;6(34):36269-36277.

Boyer T, Grardel N, Copin MC, Roumier C, Touzart A, Buchdahl AL, Corm S, Peffault de Latour R, Preudhomme C, Terriou L. Paroxysmal nocturnal hemoglobinuria (PNH) and T cell large granular lymphocyte (LGL) leukemia–an unusual association: another cause of cytopenia in PNH. Ann Hematol. 2015;94(10):1759-1760.

Bouhlel MA, Lambert M, David-Cordonnier MH. Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression. Curr Top Med Chem. 2015;15(14):1323-1358.

Boissel N, Renneville A, Leguay T, Lefebvre PC, Recher C, Lecerf T, Delabesse E, Berthon C, Blanchet O, Prebet T, Pautas C, Chevallier P, Lepretre S, Girault S, Bonmati C, Guieze R, Himberlin C, Randriamalala E, Preudhomme C, Jourdan E, Dombret H, Ifrah N. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica. 2015;100(6):780-785.

Bibault JE, Figeac M, Helevaut N, Rodriguez C, Quief S, Sebda S, Renneville A, Nibourel O, Rousselot P, Gruson B, Dombret H, Castaigne S, Preudhomme C. Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. Oncotarget. 2015;6(26):22812-22821.

Bally C, Renneville A, Preudhomme C, Legrand M, Ades L, de The H, Fenaux P, Lehmann-Che J. Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes. Leuk Res. 2015.

On-going theses (PhD)

  • LEWUILLON Clara (Y1 in 2019 – Thesis director: Yasmine TOUIL)
  • BEN-KHOUD Meriem (Y1 in 2019 – Thesis director: Carine BRINSTER)
  • HASAN BOU ISSA Lama (Y1 in 2019 – Thesis director: Salomon Manier)
  • FOVEZ Quentin (Y1 in 2018 – Thesis director: Jérôme KLUZA)
  • FLECHON Léa (Y1 in 2018 – Thesis directors: Salomon Manier/Thierry Idziorek)
  • KHAMARI Raeeka (Y1 in 2017 – Thesis director: Jérôme KLUZA)
  • GONZALES Fanny (Y1 in 2016 – Thesis director: Meyling CHEOK)

Defended theses (PhD)

  • TRINH Anne (defended 28/11/2019) directed by : Philippe MARCHETTI
  • MOPIN Alexia (defended 07/12/2018) directed by : Carine BRINSTER
  • JAMBON Samy (defended 03/12/2018) directed by : Marie-Hélène DAVID
  • MOPIN Alexia (defended 07/12/2018) directed by : Carine BRINSTER
  • BERTHE Julie (defended 07/09/2018) directed by : Bruno QUESNEL
  • LAMBERT Mélanie (defended 23/03/2018) directed by : Marie-Hélène DAVID
  • CARTON Celine (defended 15/12/2017) directed by : Thierry IDZIOREK
  • DUPLOYEZ Nicolas (defended  15/12/2017) directed by : Claude PREUDHOMME et Jean-Michel CAYUELA
  • MANIER Salomon (defended 04/07/2017) directed by : Catherine ROCHE-LESTIENNE et Xavier LELEU
  • SEGAOULA Zakaria (defended 07/04/2017) directed by : Sylvie ZOUITINA-GALIEGUE et Xavier THURU
  • ANDRE Fanny (defended 19/01/2017) directed by : Philippe MARCHETTI
  • BOYER Thomas (defended 15/12/2016) directed by : Meyling CHEOK
  • OSTYN Pauline (defended 27/09/2016) directed by : Pierre FORMSTECHER
  • POULAIN Stephanie (defended 21/09/2016) directed by : Claude PREUDHOMME
  • PORET Nicolas (defended 30/09/2015) directed by : Sylvie ZOUITINA-GALIEGUE

Defended HDR

  • MANIER Salomon (defended 18/11/2019) directed by Bruno QUESNEL
  • TOUIL Yasmine (defended 26/02/2019) directed by Bruno QUESNEL